Close Menu

NEW YORK (GenomeWeb) – Precipio Diagnostics announced today that it has priced a $2.7 million registered direct offering of equity units.

According to the company, it will offer for sale 2,748 units, each consisting of one share of Series C preferred stock convertible at $1.40 per share, and warrants to purchase up to roughly 1.9 million shares of common stock at an exercise price of $1.63 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.